GO:0008517 folic acid transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008517 describes the molecular function that moves folic acid (vitamin B9) across biological membranes.
• The reduced folate carrier SLC19A1 (RFC1) is the major bidirectional transporter for folates and antifolates in mammalian cells [1,2].
• The proton-coupled folate transporter SLC46A1 (PCFT) mediates proton-driven folate transport and is critical for intestinal folate absorption.
• Altered folic acid transport activity directly modulates antifolate drug resistance and methotrexate efficacy in leukemia cells [6,7].
• Folic acid transport is essential for purine and pyrimidine synthesis, making it a target for cancer, inflammatory and developmental research [2,6].
• CRISPR knockout, point-mutation and knock-in models allow causal testing of transporter variants and their transport phenotypes [1,7,8].
Description
Folic acid transmembrane transporter activity (GO:0008517) is the molecular function that enables the transfer of folic acid (pteroylglutamic acid) from one side of a membrane to the other. Because folates are hydrophilic vitamins that cannot diffuse freely across lipid bilayers, dedicated membrane proteins are required for their uptake and distribution. This GO term therefore captures a transport activity that is central to one-carbon metabolism and nucleotide biosynthesis. The reduced folate carrier SLC19A1 is a well-characterized system that mediates bidirectional folate transport and is a major route for antifolate drugs such as methotrexate [1,2]. Structural and functional studies have localized substrate binding determinants to transmembrane domains 7-12 of the human reduced folate carrier, and co-expression of half-molecules can restore transport activity in transport-impaired K562 cells. A second major system, the proton-coupled folate transporter SLC46A1, uses a proton gradient to drive folate transport and depends on its transmembrane domain 6-7 linker for function. Together these proteins define the physiological and pharmacological importance of GO:0008517 [2,8]. For researchers, GO:0008517 is a tractable molecular function for studying vitamin transport, antifolate resistance and drug delivery [6,7].
folic acid transmembrane transporter activity At A Glance
| GO ID | GO:0008517 |
|---|---|
| GO term | folic acid transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | folate transmembrane transporter activity; folate transporter activity; folic acid transporter activity; vitamin B9 transporter activity; vitamin M transporter activity |
| Major function | Transfer of folic acid (pteroylglutamic acid) from one side of a membrane to the other |
| Physiological role | Supports purine and pyrimidine synthesis by supplying folate cofactors |
| Representative proteins | SLC19A1 (RFC1) and SLC46A1 (PCFT) |
| Pharmacological relevance | Determines cellular uptake of antifolates such as methotrexate |
| Research methods | Transport assays, CRISPR knockout, point mutation, knock-in, overexpression and library screening |
What Is GO:0008517?
GO:0008517, folic acid transmembrane transporter activity, is a molecular function that enables the movement of folic acid (pteroylglutamic acid) across a membrane from one side to the other. Folic acid is a member of the vitamin B complex and is essential for the synthesis of purines and pyrimidines. The term includes synonymous activities such as folate transmembrane transporter activity, folate transporter activity, folic acid transporter activity, vitamin B9 transporter activity and vitamin M transporter activity. It is distinct from receptor-mediated folate binding or intracellular folate metabolism because it specifically describes transmembrane transfer.
Why Is folic acid transmembrane transporter activity Important in Cell Biology?
GO:0008517 is important because folate transport controls the intracellular supply of one-carbon units needed for nucleotide biosynthesis, and its dysfunction or pharmacological inhibition has direct consequences for cell proliferation and drug response [2,6]. The reduced folate carrier SLC19A1 is a major determinant of antifolate resistance and methotrexate efficacy in leukemia cells, and structurally altered carriers with increased folic acid transport can mediate novel resistance mechanisms [6,7]. The proton-coupled folate transporter SLC46A1 provides an additional, proton-driven route whose function depends on specific structural elements such as the transmembrane domain 6-7 linker. Because folic acid transport also influences radiation-induced apoptosis and targeted drug delivery, it is relevant to cancer therapy, drug design and basic membrane biology [3,4].
• Provides the cell with folate cofactors required for purine and pyrimidine synthesis.
• Determines sensitivity and resistance to antifolate chemotherapy such as methotrexate [6,7].
• SLC19A1-mediated transport is a major route for reduced folates and antifolates in mammalian cells [1,2].
• SLC46A1 couples folate transport to a proton gradient and is essential for intestinal folate absorption.
• Altered transport activity can change radiation-induced apoptosis responses in experimental systems.
• Folic acid targeting is used to deliver drugs such as paclitaxel in liposomal formulations.
• Transporter structure-function studies localize substrate binding to transmembrane domains 7-12 of the reduced folate carrier.
• Folate transport is a model system for understanding transmembrane signal transduction and membrane protein assembly.
• CRISPR-based models enable causal testing of transporter variants and resistance phenotypes [1,7,8].
• The term supports research in cancer, developmental biology and vitamin metabolism [2,6].
What Happens During folic acid transmembrane transporter activity?
Substrate recognition at the membrane
In simple terms: The transporter first recognizes and binds folate at the membrane surface.
Folic acid transmembrane transporter activity begins with substrate recognition by membrane-embedded transporter proteins. For the human reduced folate carrier, substrate binding determinants have been localized to transmembrane domains 7-12, and co-expression of half-molecules can restore transport activity in transport-impaired K562 cells, indicating that these domains form part of the substrate binding domain. This step is selective for folates and related antifolates, which is why the same proteins can transport methotrexate and other antifolates [2,6].
Translocation across the lipid bilayer
In simple terms: The bound folate is moved through the membrane to the other side.
After binding, the transporter undergoes conformational changes that move folic acid across the lipid bilayer. The reduced folate carrier mediates bidirectional transport, allowing folate to move down its concentration gradient. In contrast, the proton-coupled folate transporter uses a proton gradient to drive folate translocation, and its transmembrane domain 6-7 linker is functionally and mechanistically important for this process. These distinct mechanisms illustrate how GO:0008517 can be energized either by substrate gradients or by ion gradients [2,8].
Release of folate on the trans side
In simple terms: Folate is released inside the cell or on the opposite side of the membrane.
Following translocation, folic acid is released from the transporter on the trans side of the membrane. This release step supplies intracellular folate pools that feed one-carbon metabolism and nucleotide biosynthesis. Because transport is bidirectional for the reduced folate carrier, the direction of net flux depends on the folate gradient across the membrane. In transport-impaired cells, restoration of transport activity by co-expressed carrier half-molecules demonstrates that release-competent transporter assembly is required for function.
Coupling to cellular folate metabolism
In simple terms: Once inside, folate is used for building DNA and RNA precursors.
The transported folic acid enters the cellular folate pool, where it supports the synthesis of purines and pyrimidines. This link to nucleotide biosynthesis explains why folate transport activity is essential for proliferating cells and why antifolates that use these transporters can inhibit cell growth. Methotrexate efficacy in leukemia cells depends on transport mechanisms, and altered transport can produce antifolate resistance [6,7]. Thus, GO:0008517 is functionally coupled to downstream metabolic pathways rather than being an isolated transport event [2,6].
Pharmacological modulation by antifolates
In simple terms: Drugs can compete with folate for the same transporter.
Antifolates such as methotrexate are substrates for folate transporters, so changes in transporter activity directly affect drug uptake and cytotoxicity. A structurally altered human reduced folate carrier with increased folic acid transport can mediate a novel mechanism of antifolate resistance, showing that transport activity and drug response are tightly linked. This pharmacological dimension makes GO:0008517 a key consideration in chemotherapy research and in the design of folate-targeted drug delivery systems [4,6].
Key Genes Involved in GO:0008517 folic acid transmembrane transporter activity
The following genes and proteins are experimentally linked to folic acid transmembrane transporter activity or its pharmacological consequences.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC19A1 | Reduced folate carrier mediating bidirectional folate and antifolate transport | Major determinant of methotrexate uptake and antifolate resistance [1,2,6] |
| SLC46A1 | Proton-coupled folate transporter using a proton gradient for folate transport | Intestinal folate absorption and structural studies of the TMD6-7 linker |
| RFC1 | Alternative name for the reduced folate carrier protein | Substrate binding domain localized to transmembrane domains 7-12 |
| PCFT | Alternative name for the proton-coupled folate transporter | Mechanistic studies of proton-coupled transport |
| GART | Purine biosynthesis enzyme requiring folate cofactors | Downstream readout of folate supply |
| TYMS | Thymidylate synthase using folate-derived one-carbon units | Target of antifolates and folate metabolism studies [2,6] |
| MTHFR | Folate metabolism enzyme | Context for folate-dependent one-carbon flux |
| DHFR | Dihydrofolate reductase, target of methotrexate | Antifolate pharmacology and resistance studies |
| FPGS | Folylpolyglutamate synthetase | Retention of folates and antifolate activity |
| GGH | Gamma-glutamyl hydrolase | Folate polyglutamation and drug response |
| ABCB1 | Efflux transporter affecting drug resistance | Context for multidrug resistance in leukemia |
| ABCC1 | Efflux transporter affecting antifolate response | Context for transport-mediated resistance |
| K562 | Cell line used for transport-impaired complementation studies | Restoration of transport by carrier half-molecules |
| SLC19A1 variants | Structurally altered carriers with changed transport activity | Novel antifolate resistance mechanisms |
| Folate receptor proteins | Folate binding and targeting, distinct from transmembrane transport | Folic acid-targeted drug delivery |
| Pterin-related pathways | Redox and apoptosis modulation | Radiation-induced apoptosis enhancement by 6-formylpterin |
| Dictyostelium membrane proteins | Model for transmembrane signal transduction | General membrane transport and signaling context |
How Is folic acid transmembrane transporter activity Regulated?
Folic acid transmembrane transporter activity is regulated at multiple levels. Transport activity can be altered by structural changes in the transporter protein, as shown by a structurally altered human reduced folate carrier with increased folic acid transport that mediates antifolate resistance. The proton-coupled folate transporter requires its transmembrane domain 6-7 linker for function, indicating that intramolecular structural elements regulate transport. In addition, co-expression of reduced folate carrier half-molecules can restore transport activity in transport-impaired K562 cells, demonstrating that protein assembly and domain complementation regulate function. Pharmacologically, antifolate drugs compete with folates for transport, effectively modulating net transport activity. These mechanisms collectively determine cellular folate supply and drug response [2,6].
folic acid transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC19A1 | Antifolate resistance and methotrexate response in leukemia | Knockout and point-mutation leukemia cell lines [6,7] |
| SLC46A1 | Proton-coupled folate transport and intestinal absorption | Knock-in of TMD6-7 linker variants |
| RFC1 | Transport-impaired phenotype and substrate binding | Complementation in K562 cells with half-molecules |
| DHFR | Methotrexate pharmacology | Overexpression and knockout models |
| Folate receptor pathway | Folate-targeted drug delivery | Folic acid-targeted liposome models |
Antifolate resistance in leukemia
Altered folic acid transmembrane transporter activity is directly linked to antifolate resistance and methotrexate efficacy in leukemia cells. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance, showing that transport changes can shift drug sensitivity. Because methotrexate depends on folate transporters for cellular entry, changes in SLC19A1 function can reduce or enhance drug response [6,7].
Cancer therapy and folate-targeted delivery
Folic acid transport activity is relevant to cancer therapy because folate-targeted liposomes can deliver drugs such as paclitaxel to tumor cells. In addition, modulation of folate-dependent pathways can enhance radiation-induced apoptosis in experimental models. These findings connect GO:0008517 to drug delivery strategies and combination therapy research [3,4].
Folate absorption and systemic folate status
The proton-coupled folate transporter SLC46A1 mediates proton-driven folate transport, and its transmembrane domain 6-7 linker is required for function. Because folate is an essential vitamin B complex member needed for purine and pyrimidine synthesis, impaired transport can affect cellular proliferation and systemic folate status [2,8]. This makes GO:0008517 relevant to nutritional and developmental research.
From folic acid transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SLC19A1 reduce folate transport? | CRISPR knockout cell line [1,2] |
| Does a specific transporter variant alter substrate specificity? | Point-mutation knock-in [7,8] |
| Can a tagged transporter be tracked in live cells? | Tagged knock-in |
| Does overexpression increase antifolate uptake? | Overexpression cell model [6,7] |
| Which genes modify antifolate resistance? | CRISPR library screening |
| How does transporter structure affect function? | Domain-swap and half-molecule complementation [1,8] |
How to Study the folic acid transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled folate transport assay | Rate of folate flux across membranes | Quantifying GO:0008517 activity |
| Complementation assay | Restoration of transport in impaired cells | Mapping substrate binding domains |
| CRISPR knockout | Loss-of-function effect on transport | Testing SLC19A1 and SLC46A1 function [1,2] |
| Point-mutation knock-in | Effect of specific variants on transport | Studying resistance mutations [7,8] |
| CRISPR library screening | Genome-wide modifiers of antifolate resistance | Discovering resistance genes |
| Antifolate sensitivity assay | Cell growth inhibition by methotrexate | Evaluating drug response [6,7] |
| Folate-targeted liposome assay | Drug delivery to folate receptor-positive cells | Targeted cancer therapy |
| Apoptosis assay | Radiation-induced cell death | Testing folate pathway modulation |
Transport assays
Direct transport assays measure the movement of radiolabeled or fluorescent folates across membranes and are the primary way to quantify GO:0008517 activity. Complementation of transport-impaired K562 cells with reduced folate carrier half-molecules is an example of a functional transport assay that can localize substrate binding domains.
CRISPR-based genetic screens
CRISPR knockout and library screens can identify genes that modify folate transport and antifolate resistance. Such screens are useful for discovering transporters, metabolic enzymes and resistance modifiers in leukemia and other cell models [6,7].
Structural and mutational analysis
Mutational analysis of transporter domains, such as transmembrane domains 7-12 of the reduced folate carrier and the transmembrane domain 6-7 linker of the proton-coupled folate transporter, reveals structure-function relationships [1,8]. These approaches define which residues and domains are required for transport activity [1,8].
Pharmacological and drug delivery studies
Antifolate sensitivity assays and folate-targeted liposome experiments connect transport activity to drug efficacy and delivery [4,6]. These methods are used to evaluate methotrexate response and folate-targeted paclitaxel formulations [4,6].
How CRISPR Can Be Used to Study GO:0008517 folic acid transmembrane transporter activity
Knockout
CRISPR knockout of SLC19A1 or SLC46A1 can abolish folic acid transmembrane transporter activity and reveal its contribution to folate uptake, nucleotide synthesis and antifolate sensitivity [1,2]. Transport-impaired K562 cells provide a complementary system for testing whether reintroduced transporter constructs restore activity.
Point Mutation
Point mutations in transporter domains, such as transmembrane domains 7-12 of the reduced folate carrier or the transmembrane domain 6-7 linker of the proton-coupled folate transporter, can be introduced to test their effects on substrate binding and transport [1,8]. Structurally altered carriers with increased folic acid transport illustrate how point changes can produce antifolate resistance.
Knock-in
Knock-in of tagged or variant transporters allows tracking of protein localization and function in a native context [1,8]. This approach is useful for studying how specific structural elements, such as the TMD6-7 linker, contribute to proton-coupled folate transport.
Overexpression
Overexpression of folate transporters can increase cellular folate and antifolate uptake, making it a powerful tool to study transport kinetics and drug response [6,7]. Overexpression models also help determine whether increased transport activity is sufficient to change methotrexate efficacy [6,7].
How EDITGENE Supports folic acid transmembrane transporter activity Research
Researchers studying folic acid transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in folate transport, antifolate resistance or drug delivery. EDITGENE provides CRISPR-based cell models and screening services that enable functional testing of transporters such as SLC19A1 and SLC46A1 in relevant cellular backgrounds [1,2,6,7,8].
Contact EDITGENE today to design your custom CRISPR model for folic acid transmembrane transporter activity research.
Frequently Asked Questions About folic acid transmembrane transporter activity
What is folic acid transmembrane transporter activity?
It is the molecular function defined by GO:0008517 that enables the transfer of folic acid (pteroylglutamic acid) from one side of a membrane to the other.
What genes are involved in folic acid transmembrane transporter activity?
The major genes include SLC19A1 (reduced folate carrier) and SLC46A1 (proton-coupled folate transporter), which mediate folate transport across membranes [1,2,8].
What is the GO ID for folic acid transmembrane transporter activity?
The GO ID is GO:0008517, and the ontology aspect is molecular_function.
How does the reduced folate carrier transport folate?
The reduced folate carrier mediates bidirectional folate transport, and its substrate binding domain has been localized to transmembrane domains 7-12 [1,2].
What is the role of SLC46A1 in folate transport?
SLC46A1 is a proton-coupled folate transporter whose transmembrane domain 6-7 linker is required for function.
How is folic acid transport related to methotrexate resistance?
Antifolates such as methotrexate use folate transporters for uptake, and altered transport activity can mediate antifolate resistance in leukemia cells [6,7].
Can CRISPR be used to study folate transporters?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models can test the causal role of transporters in folate uptake and drug response [1,7,8].
What methods measure folic acid transmembrane transporter activity?
Transport assays, complementation assays, antifolate sensitivity tests and CRISPR screens are commonly used to measure this activity [1,2,6].
Why is folate transport important for cell growth?
Folic acid is essential for purine and pyrimidine synthesis, so its transport supports nucleotide biosynthesis and proliferation.
Is folic acid transport relevant to cancer therapy?
Yes, folate transport affects antifolate drug efficacy and is used in folate-targeted drug delivery approaches such as paclitaxel-loaded liposomes [4,6].
Conclusion
GO:0008517, folic acid transmembrane transporter activity, is a well-defined molecular function that governs the movement of vitamin B9 across membranes and connects directly to nucleotide biosynthesis, antifolate pharmacology and folate-targeted drug delivery [2,6,4]. The reduced folate carrier SLC19A1 and the proton-coupled folate transporter SLC46A1 provide complementary systems for studying substrate recognition, translocation and regulation [1,8]. CRISPR-based knockout, point-mutation, knock-in and overexpression models now make it possible to test causal relationships between transporter variants and cellular phenotypes such as methotrexate resistance [1,7,8]. Continued research on this activity will inform cancer therapy, vitamin metabolism and membrane transport biology [2,6].
References
- 1. Witt TL et al.. 2004. Restoration of transport activity by co-expression of human reduced folate carrier half-molecules in transport-impaired K562 cells: localization of a substrate binding domain to transmembrane domains 7-12.. J Biol Chem 279(45):46755-63 PMID: 15337749
- 2. Matherly LH et al.. 2003. Membrane transport of folates.. Vitam Horm 66:403-56 PMID: 12852262
- 3. Cui ZG et al.. 2004. Enhancement of radiation-induced apoptosis by 6-formylpterin.. Free Radic Res 38(4):363-73 PMID: 15190933
- 4. Zhao P et al.. 2010. Paclitaxel-loaded, folic-acid-targeted and TAT-peptide-conjugated polymeric liposomes: in vitro and in vivo evaluation.. Pharm Res 27(9):1914-26 PMID: 20582454
- 5. Janssens PM et al.. 1987. Molecular basis of transmembrane signal transduction in Dictyostelium discoideum.. Microbiol Rev 51(4):396-418 PMID: 2893972
- 6. Fotoohi AK et al.. 2008. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells.. Leuk Lymphoma 49(3):410-26 PMID: 18297517
- 7. Jansen G et al.. 1998. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance.. J Biol Chem 273(46):30189-98 PMID: 9804775
- 8. Wilson MR et al.. 2016. Functional and mechanistic roles of the human proton-coupled folate transporter transmembrane domain 6-7 linker.. Biochem J 473(20):3545-3562 PMID: 27514717
